Conventional chemotherapy is applied to all patients. Approximately half of them do not respond to therapy, indicating that there is a critical need for targeted options.
Advances in biology and computer science are enabling the discovery of unique receptors in the target cells and engineering specific and complementary ligands. These advances help identify patients that may respond positively to particular therapies with new diagnostic tools.
We are designing customized therapies to be more effective at reaching the target site and delivering the therapeutic agent where it is most needed, with the lowest probability of harmful side effects for individual patients.